TSHA Live signals | Maximize Profits with Getagraph.com

SELL 94438 min ago

@ $1.475

Issued: 14 Feb 2024 @ 15:29

Return: 53.90%

Previous signal: Feb 14 - 13:58

Previous signal: Buy

Return: 2.43 %

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 16:00):

Stats
Today's Volume	1.79M
Average Volume	2.78M
Market Cap	424.53M
EPS	$0 ( 2024-03-19 )
Next earnings date	( $-0.110 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.36
ATR14	$0.00600 (0.26%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-02	Alam Kamran	Sell	1 288	Common Stock
2024-01-02	Alam Kamran	Buy	590 413	Common Stock
2024-01-02	Alam Kamran	Buy	590 413	Employee Stock Option (right to buy)
2024-01-02	Nagendran Sukumar	Buy	863 617	Common Stock
2024-01-02	Nagendran Sukumar	Buy	863 617	Employee Stock Option (right to buy)

INSIDER POWER
95.34
Last 97 transactions
Buy: 29 865 015 \| Sell: 943 112

Volume Correlation

Long: 0.23 (neutral)

Short: 0.93 (very strong)

Signal:(50.174) Expect same movement, but be aware

Taysha Gene Therapies, Correlation

10 Most Positive Correlations
BCYC	0.922
EAR	0.92
TRMK	0.91
ALNY	0.895
DTSS	0.887
XPDI	0.882
GOEV	0.876
GMII	0.872
GOOD	0.871
ALLK	0.87

10 Most Negative Correlations
VTYX	-0.889
CNCE	-0.889
STTK	-0.888
FLXN	-0.888
DRNA	-0.886
THRY	-0.881
OCSL	-0.881
NPCE	-0.878
PLRX	-0.877
XM	-0.877

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Taysha Gene Therapies, Correlation - Currency/Commodity

-0.09
( neutral )

0.06
( neutral )

0.00
( neutral )

-0.02
( neutral )

Taysha Gene Therapies, Financials

Annual	2023
Revenue:	$15.45M
Gross Profit:	$14.08M (91.13 %)
EPS:	$-0.960

Q4	2023
Revenue:	$3.60M
Gross Profit:	$3.24M (89.84 %)
EPS:	$0.260

Q3	2023
Revenue:	$4.75M
Gross Profit:	$4.42M (93.03 %)
EPS:	$-0.930

Q2	2023
Revenue:	$2.40M
Gross Profit:	$1.69M (70.65 %)
EPS:	$-0.380

Financial Reports:

No articles found.

Taysha Gene Therapies,

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.